ALZN Alzamend Neuro, Inc.: institutional ownership and insider trading
13 funds reported holding $3.65M of Alzamend Neuro, Inc. in their latest 13F filings; in Q2 2026 funds net bought $2.44M, with 2 new positions and 3 funds selling out; over the last 12 months insiders bought $110K and sold $14.0K on the open market.
ALZN revenue and earnings
- Quarter ended Jul 31, 2026: revenue n/a, net income −$3.03M, EPS -0.68
- Quarter ended Apr 30, 2026: revenue n/a, net income −$2.87M, EPS -0.47
- Quarter ended Jan 31, 2026: revenue n/a, net income −$2.20M, EPS -0.58
- Quarter ended Oct 31, 2025: revenue n/a, net income −$1.00M, EPS -0.30
Largest institutional holders of ALZN
- Kingsbury Capital Investment Advisors LLC — $1.94M
- KMT WEALTH MANAGEMENT, LLC — $1.59M
- VANGUARD GROUP INC — $39.3K
- GEODE CAPITAL MANAGEMENT, LLC — $31.6K
- VANGUARD FIDUCIARY TRUST CO — $25.2K
- VANGUARD CAPITAL MANAGEMENT LLC — $9.07K
- Tower Research Capital LLC (TRC) — $4.22K
- UBS Group AG (UBS) — $2.82K
- BlackRock, Inc. (BLK) — $524
- SBI Securities Co., Ltd. — $38
Recent ALZN insider trades
- Aug 26, 2026: Ault Milton C Iii sold 2,000 shares ($3.12K)
- Apr 14, 2026: Ault Milton C Iii bought 110,388 shares ($110K)
- Dec 23, 2025: Ault Milton C Iii sold 1,851 shares ($3.83K)
- Dec 19, 2025: Horne William B. sold 3,333 shares ($7.07K)
Who owns the most ALZN stock?
The largest institutional holders of Alzamend Neuro, Inc. in the latest 13F filings are Kingsbury Capital Investment Advisors LLC ($1.94M), KMT WEALTH MANAGEMENT, LLC ($1.59M), VANGUARD GROUP INC ($39.3K).
Are insiders buying or selling ALZN?
Over the last 12 months insiders bought $110K and sold $14.0K of Alzamend Neuro, Inc. stock on the open market (SEC Form 4).